TYAN
22.6.2020 17:02:12 CEST | Business Wire | Press release
TYAN® , an industry-leading server platform design manufacturer and a MiTAC Computing Technology Corporation subsidiary, is showcasing its latest lineup of HPC, storage, cloud and embedded platforms powered by 2nd Gen AMD EPYC™ 7002 series processors and 2nd Gen Intel® Xeon® Scalable Processors at TYAN server solutions online exhibition .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200622005042/en/
“With over 30 years of experience offering state-of-the-art server platforms and server motherboards, TYAN has been recognized by large scale data center customers and server channels,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “Combining the latest innovation from our partners, like Intel and AMD, TYAN customers enable to win the market opportunities precisely with TYAN’s server building block offerings.”
Attendees will experience featured products showcase, webinar sessions and live Q & A during the virtual environment. Heading TYAN’s latest server offerings for the HPC community are Thunder HX FT83-B7119 and Transport HX TS75-B8252 . The FT83-B7119 is built around 2nd Gen Intel Xeon Scalable processors featuring ten double-width PCIe x16 slots for GPUs and 12 hot-swap, tool-less 3.5” drive bays which support up to 4 NVMe U.2 drives in a 4U enclosure. The system is ideal for AI training and inference applications. Powered by 2nd Gen AMD EPYC 7002 series processors, the TS75-B8252 is optimized for virtualization, AI inference and in-memory computing workloads. The 2U server platform features 32 DIMM slots, up to 9 PCIe 4.0 slots, 12 hot-swap, tool-less 3.5” drive bays which support up to 4 NVMe U.2 drives.
Optimized for the challenges facing in Cloud Server Providers, TYAN’s cloud platforms offer outstanding computing density and storage performance in a cost-efficient way. The new 1U Thunder SX GT93-B7106 supports dual socket 2nd Gen Intel Xeon Scalable processors with twelve 3.5” and one 2.5” easy-swap drive bays for software-defined cold storage applications. Featuring 2nd Gen AMD EPYC 7002 series processors, the Transport CX GC68-B8036 accommodates four 3.5” and four 2.5” hot-swap, tool-less drive bays in 1U for both data storage and application cache requirement in data center deployment; the Transport CX TN73-B8037-X4S is a 2U 4-node high-density server platform with support for 16 hot-swap, tool-less 2.5” drive bays supporting both NVMe U.2 and SATA devices. The system is ideal for high IOPs server use cases in data centers.
TYAN offers a full line of storage servers capable of storing massive amounts of data, ranging from 1U high-performance storage server with 12 all-flash drive bays, 2U hybrid storage server to enormous 4U high capacity 100-drive high capacity one. TYAN storage server product line provides a variety of selection for tiered storage requirements in enterprises and data centers.
Please click here for more information and to register.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200622005042/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom